StreetInsider.com News Articles

Apotex Announces First Quarter 2027 Results

Wed, 12 Aug 2026 05:59:00 -0400

– Canada Delivers 11% Revenue Growth in Q1

– Adjusted EBITDA¹ of $259 Million with 31% Margin

– Launch Momentum Supports FY 2027 Guidance: Upper Mid-Single Digit Revenue Growth and ~ 30% Adjusted EBITDA Margin

– Successfully Completed Upsized IPO and Applied $800 Million of Proceeds to Debt Repayment

TORONTO, Aug. 12, 2026 /PRNewswire/ -- Apotex Health Corp. ("Apotex" or the "Company") (TSX: APTX), a Canadian-based global health company and Canada's largest pharmaceutical company, today announced its financial and operating results for the three months ended June 30, 2026. All financial figures

Apotex Announces First Quarter 2027 Results

Wed, 12 Aug 2026 05:59:00 -0400

– Canada Delivers 11% Revenue Growth in Q1

– Adjusted EBITDA¹ of $259 Million with 31% Margin

– Launch Momentum Supports FY 2027 Guidance: Upper Mid-Single Digit Revenue Growth and ~ 30% Adjusted EBITDA Margin

– Successfully Completed Upsized IPO and Applied $800 Million of Proceeds to Debt Repayment

Apotex Announces First Quarter 2027 Results

Wed, 12 Aug 2026 05:59:00 -0400

– Canada Delivers 11% Revenue Growth in Q1

– Adjusted EBITDA¹ of $259 Million with 31% Margin

– Launch Momentum Supports FY 2027 Guidance: Upper Mid-Single Digit Revenue Growth and ~ 30% Adjusted EBITDA Margin

– Successfully Completed Upsized IPO and Applied $800 Million of Proceeds to Debt Repayment

Apotex Announces First Quarter 2027 Results

Wed, 12 Aug 2026 05:59:00 -0400

– Canada Delivers 11% Revenue Growth in Q1

– Adjusted EBITDA¹ of $259 Million with 31% Margin

– Launch Momentum Supports FY 2027 Guidance: Upper Mid-Single Digit Revenue Growth and ~ 30% Adjusted EBITDA Margin

– Successfully Completed Upsized IPO and Applied $800 Million of Proceeds to Debt Repayment

Apotex Announces First Quarter 2027 Results

Wed, 12 Aug 2026 05:59:00 -0400

– Canada Delivers 11% Revenue Growth in Q1

– Adjusted EBITDA¹ of $259 Million with 31% Margin

– Launch Momentum Supports FY 2027 Guidance: Upper Mid-Single Digit Revenue Growth and ~ 30% Adjusted EBITDA Margin

– Successfully Completed Upsized IPO and Applied $800 Million of Proceeds to Debt Repayment

Apotex Announces First Quarter 2027 Results

Wed, 12 Aug 2026 05:59:00 -0400

– Canada Delivers 11% Revenue Growth in Q1

– Adjusted EBITDA¹ of $259 Million with 31% Margin

– Launch Momentum Supports FY 2027 Guidance: Upper Mid-Single Digit Revenue Growth and ~ 30% Adjusted EBITDA Margin

– Successfully Completed Upsized IPO and Applied $800 Million of Proceeds to Debt Repayment

Apotex Announces First Quarter 2027 Results

Wed, 12 Aug 2026 05:59:00 -0400

– Canada Delivers 11% Revenue Growth in Q1

– Adjusted EBITDA¹ of $259 Million with 31% Margin

– Launch Momentum Supports FY 2027 Guidance: Upper Mid-Single Digit Revenue Growth and ~ 30% Adjusted EBITDA Margin

– Successfully Completed Upsized IPO and Applied $800 Million of Proceeds to Debt Repayment

Apotex Announces First Quarter 2027 Results

Wed, 12 Aug 2026 05:59:00 -0400

– Canada Delivers 11% Revenue Growth in Q1

– Adjusted EBITDA¹ of $259 Million with 31% Margin

– Launch Momentum Supports FY 2027 Guidance: Upper Mid-Single Digit Revenue Growth and ~ 30% Adjusted EBITDA Margin

– Successfully Completed Upsized IPO and Applied $800 Million of Proceeds to Debt Repayment

Apotex Announces First Quarter 2027 Results

Wed, 12 Aug 2026 05:59:00 -0400

– Canada Delivers 11% Revenue Growth in Q1

– Adjusted EBITDA¹ of $259 Million with 31% Margin

– Launch Momentum Supports FY 2027 Guidance: Upper Mid-Single Digit Revenue Growth and ~ 30% Adjusted EBITDA Margin

– Successfully Completed Upsized IPO and Applied $800 Million of Proceeds to Debt Repayment

Apotex Announces First Quarter 2027 Results

Wed, 12 Aug 2026 05:59:00 -0400

– Canada Delivers 11% Revenue Growth in Q1

– Adjusted EBITDA¹ of $259 Million with 31% Margin

– Launch Momentum Supports FY 2027 Guidance: Upper Mid-Single Digit Revenue Growth and ~ 30% Adjusted EBITDA Margin

– Successfully Completed Upsized IPO and Applied $800 Million of Proceeds to Debt Repayment

Apotex Announces First Quarter 2027 Results

Wed, 12 Aug 2026 05:59:00 -0400

– Canada Delivers 11% Revenue Growth in Q1

– Adjusted EBITDA¹ of $259 Million with 31% Margin

– Launch Momentum Supports FY 2027 Guidance: Upper Mid-Single Digit Revenue Growth and ~ 30% Adjusted EBITDA Margin

– Successfully Completed Upsized IPO and Applied $800 Million of Proceeds to Debt Repayment

Apotex Announces First Quarter 2027 Results

Wed, 12 Aug 2026 05:59:00 -0400

– Canada Delivers 11% Revenue Growth in Q1

– Adjusted EBITDA¹ of $259 Million with 31% Margin

– Launch Momentum Supports FY 2027 Guidance: Upper Mid-Single Digit Revenue Growth and ~ 30% Adjusted EBITDA Margin

– Successfully Completed Upsized IPO and Applied $800 Million of Proceeds to Debt Repayment

Apotex Announces First Quarter 2027 Results

Wed, 12 Aug 2026 05:59:00 -0400

– Canada Delivers 11% Revenue Growth in Q1

– Adjusted EBITDA¹ of $259 Million with 31% Margin

– Launch Momentum Supports FY 2027 Guidance: Upper Mid-Single Digit Revenue Growth and ~ 30% Adjusted EBITDA Margin

– Successfully Completed Upsized IPO and Applied $800 Million of Proceeds to Debt Repayment

Apotex Announces First Quarter 2027 Results

Wed, 12 Aug 2026 05:59:00 -0400

– Canada Delivers 11% Revenue Growth in Q1

– Adjusted EBITDA¹ of $259 Million with 31% Margin

– Launch Momentum Supports FY 2027 Guidance: Upper Mid-Single Digit Revenue Growth and ~ 30% Adjusted EBITDA Margin

– Successfully Completed Upsized IPO and Applied $800 Million of Proceeds to Debt Repayment

Apotex Announces First Quarter 2027 Results

Wed, 12 Aug 2026 05:59:00 -0400

– Canada Delivers 11% Revenue Growth in Q1

– Adjusted EBITDA¹ of $259 Million with 31% Margin

– Launch Momentum Supports FY 2027 Guidance: Upper Mid-Single Digit Revenue Growth and ~ 30% Adjusted EBITDA Margin

– Successfully Completed Upsized IPO and Applied $800 Million of Proceeds to Debt Repayment

Apotex Announces First Quarter 2027 Results

Wed, 12 Aug 2026 05:59:00 -0400

– Canada Delivers 11% Revenue Growth in Q1

– Adjusted EBITDA¹ of $259 Million with 31% Margin

– Launch Momentum Supports FY 2027 Guidance: Upper Mid-Single Digit Revenue Growth and ~ 30% Adjusted EBITDA Margin

– Successfully Completed Upsized IPO and Applied $800 Million of Proceeds to Debt Repayment

Apotex Announces First Quarter 2027 Results

Wed, 12 Aug 2026 05:59:00 -0400

– Canada Delivers 11% Revenue Growth in Q1

– Adjusted EBITDA¹ of $259 Million with 31% Margin

– Launch Momentum Supports FY 2027 Guidance: Upper Mid-Single Digit Revenue Growth and ~ 30% Adjusted EBITDA Margin

– Successfully Completed Upsized IPO and Applied $800 Million of Proceeds to Debt Repayment

Apotex Announces First Quarter 2027 Results

Wed, 12 Aug 2026 05:59:00 -0400

– Canada Delivers 11% Revenue Growth in Q1

– Adjusted EBITDA¹ of $259 Million with 31% Margin

– Launch Momentum Supports FY 2027 Guidance: Upper Mid-Single Digit Revenue Growth and ~ 30% Adjusted EBITDA Margin

– Successfully Completed Upsized IPO and Applied $800 Million of Proceeds to Debt Repayment

Apotex Announces First Quarter 2027 Results

Wed, 12 Aug 2026 05:59:00 -0400

– Canada Delivers 11% Revenue Growth in Q1

– Adjusted EBITDA¹ of $259 Million with 31% Margin

– Launch Momentum Supports FY 2027 Guidance: Upper Mid-Single Digit Revenue Growth and ~ 30% Adjusted EBITDA Margin

– Successfully Completed Upsized IPO and Applied $800 Million of Proceeds to Debt Repayment

Apotex Announces First Quarter 2027 Results

Wed, 12 Aug 2026 05:59:00 -0400

– Canada Delivers 11% Revenue Growth in Q1

– Adjusted EBITDA¹ of $259 Million with 31% Margin

– Launch Momentum Supports FY 2027 Guidance: Upper Mid-Single Digit Revenue Growth and ~ 30% Adjusted EBITDA Margin

– Successfully Completed Upsized IPO and Applied $800 Million of Proceeds to Debt Repayment

Apotex Announces First Quarter 2027 Results

Wed, 12 Aug 2026 05:59:00 -0400

– Canada Delivers 11% Revenue Growth in Q1

– Adjusted EBITDA¹ of $259 Million with 31% Margin

– Launch Momentum Supports FY 2027 Guidance: Upper Mid-Single Digit Revenue Growth and ~ 30% Adjusted EBITDA Margin

– Successfully Completed Upsized IPO and Applied $800 Million of Proceeds to Debt Repayment

Apotex Announces First Quarter 2027 Results

Wed, 12 Aug 2026 05:59:00 -0400

– Canada Delivers 11% Revenue Growth in Q1

– Adjusted EBITDA¹ of $259 Million with 31% Margin

– Launch Momentum Supports FY 2027 Guidance: Upper Mid-Single Digit Revenue Growth and ~ 30% Adjusted EBITDA Margin

– Successfully Completed Upsized IPO and Applied $800 Million of Proceeds to Debt Repayment

Apotex Announces First Quarter 2027 Results

Wed, 12 Aug 2026 05:59:00 -0400

– Canada Delivers 11% Revenue Growth in Q1

– Adjusted EBITDA¹ of $259 Million with 31% Margin

– Launch Momentum Supports FY 2027 Guidance: Upper Mid-Single Digit Revenue Growth and ~ 30% Adjusted EBITDA Margin

– Successfully Completed Upsized IPO and Applied $800 Million of Proceeds to Debt Repayment

Apotex Announces First Quarter 2027 Results

Wed, 12 Aug 2026 05:59:00 -0400

– Canada Delivers 11% Revenue Growth in Q1

– Adjusted EBITDA¹ of $259 Million with 31% Margin

– Launch Momentum Supports FY 2027 Guidance: Upper Mid-Single Digit Revenue Growth and ~ 30% Adjusted EBITDA Margin

– Successfully Completed Upsized IPO and Applied $800 Million of Proceeds to Debt Repayment

Apotex gets BBB (low) rating, revises credit deal with $1.2B facility

Thu, 16 Jul 2026 15:30:11 -0400

Apotex Health Corp. (TSX: APTX) announced the completion of an amended and restated credit agreement after receiving an inaugural BBB (low) investment-grade issuer rating from Morningstar DBRS, according to a press release dated July 16, 2026.

The amended credit agreement includes updated pricing and fees that reflect the new investment-grade rating, resulting in lower borrowing costs for the Toronto-based pharmaceutical company. The agreement also provides covenants offering greater operational flexibility.

The credit facility includes term loan facilities and a revolving credit facility with a total capacity of $1.2 billion. The Bank of Nova Scotia serves as administrative agent, with The Bank of